Member Info for Laura2022

May well be worth adding more to bring your price down, I have only recently come across this compa y when I was researching new energy stocks and also the First Equity Mr Black purchases as he has been buying a lot of smaller companies like NTQ and GTC and otjers

Looks like the 4th ID in 4 weeks

My buy STILL hasn't shown up from yesterday afternoon

Hello draft

I'm not sure but £750,000 is very good and now GTC has

£3mln annual recurring revenues

Had reduced losses from £2mln to £500k and now complety debt free

Key new energy markets like thermal and hydrogen

New TR1 buyer who has gone from 3% to 10% (Black estate)

Thereby eliminating all Company borrowings and significantly improving the Company's financial position.

Fantastic news

Recurring revenue same as mark cap and now this assert sale

Getech, a world-leading locator of subsurface resources, is pleased to announce the sale of its headquarters building, Nicholson House.

On 3rd February 2025 the Company exchanged contracts on the sale of its freehold interest in Nicholson House for a sale price of £725,000, including receipt of a non-refundable deposit of £72,500, with completion set for 27th February 2025.

On completion, a portion of the net proceeds will be used to repay the balance outstanding on the Company's bridge loan facility (c. £420,000) and other transaction fees, thereby eliminating all Company borrowings and significantly improving the Company's financial position.

Would dovetail.nicely with THRU

Thruvision's patented technology is uniquely capable of detecting concealed objects in real time using an advanced AI-based detection algorithm. The Group's offices are near Oxford and Washington DC

"As such, the Board wishes to explore its strategic options in a coordinated fashion, alongside engaging with a range of potentially interested parties."

From the Jan 2025 strategy update

Good evening hopist

Interesting developments also at THRU and GTC if you see last few RNS

Might grab some LLAI but have to fill some US marker compatibility form for LLAI

The reason this company has turned on challenging times is because when Biden took over the White House, the orders generated by the US customs and border protection (CBP) dried up, his administration froze this spending.. previously this US customs and border force was the biggest customer.Now in less than a week Trump comes back to power, I suspect this will lead to these orders returning and this will likely generate a return to a strong order book in the next 12 months.....If they want to sell the business they need to factor this in to the price..

74827 shares

Not shown

My buy hadn't shown ?

Lots of ifs and buts

However, maybe worth a flutter ?

The potential contract value from the Material Opportunities for the financial year ending 31 March 2026 is approximately £15 million, and it is expected that there would be follow-on sales of units, software and support.

Had to pay 2.17p

Now £2k is NT at 2 3p

Still no st0ck

Still cannot purchase online

Another disastrous IPO

Stich up by major holders

Significant ShareholdingsSignificant shareholdersNo of Common Shares% of share capitalSimon Raab4,148,29313.5Unicorn Asset Management3,907,14212.7Icahn School of Medicine at Mount Sinai2,469,8428.0Lombard Odier Asset Management2,429,7087.9Octopus Investments1,968,7506.4Frederick Gluck1,757,3535.7Stifel Nicolaus & Co1,581,6685.2SYNO Ventures Master Fund LP1,377,3254.5Livzon Pharmaceutical Group Inc1,347,6534.4Winterflood Securities1,096,4773.6Investec Wealth & Investment1,003,0653.3Accord Data Holdings954,0483.1

Not good

The Company proposes to seek to reengage with parties regarding the securing of a strategic partner for LungLife. However, in light of the cash runway available to the Company and the lack of interest in a fundraising, it has now become clear to the Board that the most appropriate course of action is for the Board to seek approval from the shareholders of the Company to cancel the admission of the Company's ordinary shares to trading on AIM in accordance with Rule 41 of the AIM Rules for Companies.

 

A circular convening a general meeting of the Company to approve the proposed cancellation and providing further detail on the next steps will be published in due course and a further announcement will be made at that time.

 

The Board proposes to continue to consider potential sources of funding options for the Company but, should none be identified, nor any strategic agreement reached, the Board anticipates the orderly winding up of the business in due course. 

 

Inaphaea Evaluation and Commercial Use Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of an Evaluation and Commercial Use agreement ("Agreement") with UK based Screenin3d Limited ("Screenin3D") to provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and commercial use in Screenin3D's state-of-the-art UpScale3Dlab-on-a-chip technology with associated image analysis software. The Agreement initially focusses on establishment of three Triple Negative Breast Cancer in-vitro 3D tumour model which will then be offered for commercial services by Screenin3D and Inaphaea. Additional PDCs across Inaphaea's range of 66 cancer types can be added at any time.

Poulton has done the dirty on WSBN shareholders see last RNS

I can't understand why sane people put money in companies run by crooks like Bell, Roach, Bird , Poulden etc when it's clear they've lied to investors for a decade